PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center

LITTLE RIVER, S.C., Jan. 10, 2019 (GLOBE NEWSWIRE) -- PCT LTD (OTC Pink: PCTL), through its operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp), a leader in environmentally safe, non-toxic, antimicrobial solutions for infection control, secured a three-year Master Service Agreement and recently installed its Annihilyzer® Infection Control System at Carson Tahoe Regional Medical Center in Carson City, NV.  Carson Tahoe conducted in-house evaluations at their facility and produced several articles regarding the use of Hypochlorous Acid for cleaning and disinfecting surfaces in a hospital environment to reduce colony forming microorganism contamination.  Hospital Associated Infections (HAI’s) currently costs U.S. hospitals over $35 Billion in infection prevention and control programs, HAI patient treatment and other significant HAI-associated costs.

PCT’s Annihilyzer® Infection Control System is capable of onsite production of a non-harmful, Green Seal Certified tuberculocidal disinfectant that is effective against 99.9999% of organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas.  The Company's primary disinfecting fluid solution is effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, H1N1, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella.  This group was very excited about the ability to reduce Hospital Associated Infections (HAI) using a non-synthetic solution which is not harmful to patients, staff, equipment, or furniture. The ability to track the fluid’s efficacy and provide cleaning and disinfecting protocols will reduce human error and increase the effectiveness of infection prevention and disinfection programs.

Dr. Raymond Swarts, Infectious Diseases Specialist stated, "We are pleased that our Environmental Services department will have unlimited access to an environmentally friendly disinfectant with greater killing activity than bleach without the harmful side effects. This disinfectant containing Hypochlorous acid will be produced on station and its efficacy will be monitored at all times. The favorable pH monitoring will ensure its efficacy and limit any corrosive effects to hospital equipment."

Jody Read, CEO of PCT Ltd  stated, “Carson Tahoe has proven that the use of the fluids produced by PCT’s Annihilyzer System can be beneficial for reducing hospital costs associated with the spread of bacteria within a facility, reducing the opportunity for Hospital Associated Infections from surface contamination, treating more than just confined spaces without harming patients, staff, equipment, or furniture, by using a safe, non-synthetic, green product.”

The market potential of PCT’s system in hospitals is approximately 7,000 systems across the US and for Nursing Homes and Assisted Living facilities is approximately 13,600 systems.  PCT has a current sales funnel of over 30 United States hospitals in the Carolinas and the Northeast that are in active discussions with PCT about acquiring the Annihilyzer® System and Services.  This System can significantly address and reduce the problem of Hospital Acquired Infections.


PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products.  The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp).  Currently trading on OTC, “PCTL” aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange.  The Company established entry into its target markets with commercially-viable products and now prepares to gain market share.

PCT Corp’s business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI's) from organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas, as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution, branded Hydrolyte®, is an EPA registered "hospital-level" disinfectant effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, H1N1, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Infection Control Systems, and 3) SurvivaLyte® equipment. The Hydrolyte® Generators produce large volumes of electrolyzed water for the agriculture, oil and gas, and fluid distribution markets. The Annihilyzer® Infection Control Systems, which boast patented RFID material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The SurvivaLyte® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness, remote on-site needs, farm and ranch, and personal use. PCT Corp's unique patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: any implied or perceived benefits resulting to the installation of PCT’s Annihilyzer® systems in hospitals; the results of any manufacturers’ representative and/or license agreements, actual sales revenue to be derived from  agreements; PCT LTD's and its subsidiary’s business prospects; PCT LTD’s ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCT LTD to execute its business plan or list its common stock on a national stock exchange; benefits of the Annihilyzer® Infection Control Systems, Hydrolyte® generators and fluids; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated.

Important factors that could cause actual results to differ materially from the forward-looking statements PCT LTD makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the United States Securities Exchange Commission. PCT LTD undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


Gary Grieco, Chairman of the Board
Jody Read, CEO and COO
(843) 390-7900 Office
(843) 390-2347 Fax

Brokers and Analysts:
Chesapeake Group


You May Also Like

Endocyte Reports First Quarter 2016 Financial Results

- Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented ...

Immune Design to Present at Upcoming Investor Conferences

SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design ...